I am writing this on the last day of the 8th World Congress on Alternatives and Animal Use in the Life Sciences. However, rather than being in Montreal among friends, with a glowing feeling that sound Three Rs-based progress is being made throughout the world, I am at home, being stared at by a number of documents, which suggest that the good news from Montreal reflects what is happening in some kind of parallel universe, lightyears away from the reality of biomedical science as it is practised in the UK.
The first of these documents is the Home Office Statistics of Scientific Procedures on Living Animals Great Britain 2010, 1 which Michelle Hudson has reviewed at length in this issue of ATLA. 2 The other documents will shortly be reviewed in depth, in forthcoming issues of the journal.
The number of procedures conducted in Britain continues to rise, and, at just over 3.7 million in 2010, was 3% more than in 2009, and 1 million more than the number conducted in 2001 -the year which saw the lowest number since procedures began to be included in the publication of the annual statistics, in 1987. Again, the increase was mostly due to the continuing, and seemingly uncontrolled, increase in the breeding and use of genetically-altered animals, but there was also a 23% increase in the number of procedures involving birds, and a 10% increase in procedures involving non-human primates (NHPs) to 4,688 procedures, most of which (3, 585) involved old world monkeys.
The Animals (Scientific Procedures) Bill 1985 was allowed an easy ride through the parliamentary process, not least because expectations were raised that the new law would lead to a steady, year-on-year reduction in laboratory animal use. That has not happened, and the number of procedures conducted in 2010 was back to that of 1987, in the first year of the Animals (Scientific Procedures) Act 1986 (ASPA). The Government is taking one very tiny step in dealing with this problem -a ban on the use of animals for testing household products is being introduced. 3 In 2010, 24 rats were used for this purpose.
The second document before me, entitled Review of Research Using Non-Human Primates, 4 is the report of a panel chaired by Sir Patrick Bateson, commissioned by the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC) and the Wellcome Trust, in response to a recommendation in the earlier Weatherall Report 5 that the major funding bodies should undertake a review of the outcome of all their work involving NHPs. Given its provenance, it would have been unwise to expect very much of this report. It does concede that the funding bodies should be more demanding of those who receive their funding, since it concludes that about one in 10 projects provides no clear scientific, medical or social benefits, and concedes that, for a number of projects, the justification for using monkeys was not compelling. The panel considered 31 neuroscience studies, most of which involved the use of macaques, and about half of which involved considerable animal suffering. The panel found little direct evidence of medical benefit in terms of new treatment or changes in clinical practice. Two of the studies which had a high welfare impact were assessed as only 'medium' against the 'quality of science' criterion. The three organisations which commissioned the report quickly produced a response to the 15 recommendations in the Bateson report. 6 It has long been a matter of concern that the benefits of fundamental research on animals cannot be predicted or even identified, but the Bateson panel's view -that it is acceptable that procedures of substantial severity should be applied to the higher NHPs, when those doing the work cannot say what the benefits might be -is contrary to all that was promised when the ASPA was introduced. Perhaps because it is not just what is done and why that counts, but who does it, and where.
The third document is a report on Animals containing human material (ACHM), 7 prepared for the Academy of Medical Sciences by a working group chaired by Professor Martin Bobrow, and reviewed on behalf of the Academy's Council by another group, chaired by Professor Ronald Laskey. The production of the report was partly supported by the MRC and the Wellcome Trust. The working group was set up in 2009, because of concerns that the creation and use of this type of altered animal in the name of medical research might go too far.
The members of the working group concluded that the majority of ACHM studies do not raise
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issues above those involved in the general use of animals in research, and that humanising animals for the sake of medical research does not create significant new ethical problems. It is admitted that the need for ACHM is based on the fact that findings from animals are not good predictors of what happens in humans, because of species differences. The report does recognise that safety could be an issue, e.g. if animals are made susceptible to infections normally confined to humans. It proposes that a national expert committee should advise the Government on ACHM, and that the Animal Procedures Committee should perform that function. Three topics are identified as needing special attention, namely, research involving the brain, the reproductive system or human appearance or behavioural traits. Three categories of ACHM experiments are proposed: those which do not raise issues beyond those involved in general laboratory animal use; those that demand strong scientific justification, and which should have specialist scrutiny on a case-by-case basis; and those which should not be permitted, for scientific or ethical reasons.
On the whole, the report is a very good one, although, as in the case of many others before it, including the Weatherall and Bateson reports, it largely seems to say the kind of things its sponsors would like to hear. Two fundamental points, in addition to my ethical concerns, lead me to continue to believe that this kind of research should be discouraged, since medical research should have a more-direct human focus. Firstly, as with all animal models, not enough is known about the human disease under consideration for sound judgements to be made as to whether or not the model and the information it provides are relevant. Indeed, very often, as Jarrod Bailey pointed out in an excellent letter to the editor in The Times on seeing the Bobrow report, 8 we know from the evidence that animal models of human disease do not replicate the human pathology or the symptoms. Secondly, I doubt whether the complex network of control systems in the animal, be they molecular, cellular and genetic, or whether they involve the neural, hormonal and/or immune systems, will allow the expression of the desired human characteristics in ACHM in ways which will be convenient for researchers. In other words, the outcome of ACHM studies may frequently be to introduce new, and unfathomable, degrees of uncertainty.
The next two documents are concerned with the operation of the EU system for the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), and are published by the European Chemicals Agency (ECHA), Helsinki, Finland. They are concerned with the position in 2011 with regard to The Operation of REACH and CLP, 9 where CLP = Classification, Labelling and Packaging, and The Use of Alternatives to Testing on Animals for the REACH Legislation. 10 A short summary is available for each of them. These two documents report on the early stages of the application of the REACH system, and add 150 densely-filled pages to the thousands of pages of information and guidance already published by the ECHA. In additon, there are thousands of pages of comment from stakeholders, and these will surely be added to by reactions to the two ECHA reports. Indeed, some very incisive comments by various stakeholders have already been published in Chemical Watch European Business Briefing. 11 One of the problems with the REACH system is that only the largest organisations can afford to appoint the full-time teams needed to keep a watching brief, as FRAME soon recognised. This represents a very serious problem for small and medium-sized companies, which have obligations under the REACH system, and it has led to the establishment of other companies and independent consultancies, to provide assistance for them.
The fundamental problems remain, of course: What will be the cost to companies (and eventually to consumers) of compliance with the system? What will be the cost in terms of suffering to the animals used in the further testing that will be required? Who will objectively and independently judge whether all the effort and expenditure has been worthwhile in terms of the purported intention of the system, namely, the better protection of human health and of the environment?
The final document I want to mention is the Home Office Consultation on Options for the Transposition of European Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes. This is a 45-page summary by the Home Office, containing many questions on which comments from stakeholders are sought -published on 13 June, with replies due by 5 September. The options documents and the reply document, together with some other background documents, can be found on the Home Office website. 12 It is likely that the Home Office will be overwhelmed with exhaustive feedback coming from many different quarters. FRAME's comments will have been submitted on time, and I will use our concluding thoughts to close this editorial.
Our position is that FRAME has always been supportive of Directive 86/609/EEC and of the Animals (Scientific Procedures) Act 1986 as ways of regulating animal experimentation in the EU as a whole, and specifically in the UK. However, we do recognise the need to produce a new EU Directive, in order to ensure the harmonisation of the regulations and their application in the now-expanded number of Member States in the EU.
We also recognise that some changes to the ASPA will be necessary, so that its provisions are consistent with those of Directive 63/2010/EU. However, we believe that such changes should be kept to an absolute minimum, so that the high standards applied in the UK, in the interests of both animals and science, are maintained. In particular, changes should not be introduced for the sake of bringing practice in the UK closer to the minimum standards now practised in the EU as a whole, because they would result in lower costs to the taxpayer and/or to animal users, or because they would make life easier for scientists, laboratories or companies. Any weakening of the provisions of the ASPA and their application would inevitably result in an increase in the suffering caused to laboratory animals, at great cost to them and in pursuit of benefits to human beings. These costs are already too high, and any attempt to increase them for legislative, financial or administrative reasons should be vigorously opposed.
We firmly believe that our comments would help to protect the essential fine balance between science and animal welfare. 
Michael Balls

